Adolescents can be immunized against pertussis; just last month, the Food and Drug Administration put its seal of approval on not one but two such vaccines-Adacel (Sanofi Pasteur) and Booxtrix (GlaxoSmithKline). Whether all teenagers should be vaccinated is another question, however, and one of supreme interest to pediatricians.
Adolescents can be immunized against pertussis; just last month, the Food and Drug Administration put its seal of approval on not one but two such vaccines-Adacel (Sanofi Pasteur) and Booxtrix (GlaxoSmithKline). Whether all teenagers should be vaccinated is another question, however, and one of supreme interest to pediatricians.
Cost-effectiveness analyses are performed to answer that kind of question, and the June 2005 issue of Pediatrics contains just such an examination. The authors used a computer simulation to evaluate the potential health benefits, risks, and costs of a national pertussis vaccination program for adolescents alone, or for adolescents and adults. Data on disease prevalence, vaccine efficacy and adverse effects, and vaccine cost were fed into the model.
The authors found that, from a societal perspective, one-time adolescent vaccination would prevent 36% of projected pertussis cases, with mostly mild adverse events. Assuming the cost of vaccination to be $15 and 76% of the teenage population is covered, one-time adolescent vaccination would cost $1,100 per case prevented, or $20,000 per quality-adjusted life-year-amounts considered sufficiently cost-effective by many researchers. Adult vaccination strategies, the authors found, were more costly and less effective than adolescent strategies.
The conclusion? Given the model's assumptions, routine pertussis vaccination of adolescents will result in net health benefits to that age group, and may be relatively cost-effective. The impact that adolescent immunization would have on pertussis in infants wasn't examined.
Prehospital medication dosing deviates from recommended weight-based guidelines
July 20th 2023Lorazepam, diazepam, midazolam, fentanyl, hydromorphone, morphine, ketorolac, epinephrine, diphenhydramine, and methylprednisolone were investigated in the study. Overall, the most common type of deviation was an underdose.
Having "the talk" with teen patients
June 17th 2022A visit with a pediatric clinician is an ideal time to ensure that a teenager knows the correct information, has the opportunity to make certain contraceptive choices, and instill the knowledge that the pediatric office is a safe place to come for help.
Does stimulant medication for pediatric ADHD affect adult height?
November 8th 2022A recent review found that multiple clinical trials indicated a reduction in adult height potential for children with long-term use of stimulant medication for treatment of ADHD, but other studies conflict with this data.
Diagnosing and treating the adolescent with irregular menstruation
October 10th 2022At the 2022 AAP National Conference & Exhibition, a professor from the Baylor College of Medicine discusses how to develop an approach to investigate menstrual disturbances for adolescent patients and understand treatment options.